The estimated Net Worth of Robert M Davis is at least $36.7 Million dollars as of 25 June 2019. Mr. Davis owns over 216,718 units of Merck & Co stock worth over $30,100,782 and over the last 13 years he sold MRK stock worth over $0. In addition, he makes $6,620,840 as Executive Vice President, Global Services, and Chief Financial Officer at Merck & Co.
Mr. Davis MRK stock SEC Form 4 insider trading
Robert has made over 6 trades of the Merck & Co stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 216,718 units of MRK stock worth $18,408,027 on 25 June 2019.
The largest trade he’s ever made was exercising 216,718 units of Merck & Co stock on 25 June 2019 worth over $18,408,027. On average, Robert trades about 16,391 units every 92 days since 2006. As of 25 June 2019 he still owns at least 354,377 units of Merck & Co stock.
You can see the complete history of Mr. Davis stock trades at the bottom of the page.
Robert Davis biography
Robert M. Davis Executive Vice President, Global Services, and Chief Financial Officer of the company since April 2016 prior to this he was Executive Vice President and Chief Financial Officer from April 2014-April 2016 Corporate Vice President and President, Medical Products, Baxter International, Inc. (October 2010-March 2014) Mr. Davis is responsible for the Company’s global financial organization, investor relations, corporate strategy and business development, global facilities, and the Company’s joint venture relationships. Prior to starting his employment with the Company, Mr. Davis served as Corporate Vice President and President, Medical Products of Baxter International, Inc. (“Baxter”), a healthcare company, a position he had held since October 2010. In that position, Mr. Davis was responsible for all aspects of commercial, R&D, quality, regulatory, manufacturing and supply chain functions. Prior to that position, Mr. Davis served as Corporate Vice President and President, Renal Division of Baxter in 2010 and had previously served as Baxter’s Corporate Vice President and Chief Financial Officer from 2006 to 2010.
What is the salary of Robert Davis?
As the Executive Vice President, Global Services, and Chief Financial Officer of Merck & Co, the total compensation of Robert Davis at Merck & Co is $6,620,840. There are 2 executives at Merck & Co getting paid more, with Kenneth Frazier having the highest compensation of $20,934,500.
How old is Robert Davis?
Robert Davis is 52, he’s been the Executive Vice President, Global Services, and Chief Financial Officer of Merck & Co since 2016. There are 19 older and 2 younger executives at Merck & Co. The oldest executive at Merck & Co., Inc. is Thomas Cech, 72, who is the Independent Director.
What’s Robert Davis’s mailing address?
Robert’s mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD,, IL, 60015.
Insider trading at Merck & Co
Over the last 10 years, insiders at Merck & Co have traded over $53,837,709 worth of Merck & Co stock and bought 47,800 units worth $1,519,400 . The most active insider traders include Wendell P Weeks, Kenneth C Frazier, and Adam H Schechter. On average, Merck & Co executives and independent directors trade stock every 15 days with the average trade being worth of $3,440,102. The most recent stock trade was executed by Steven Mizell on 30 October 2019, trading 4,574 units of MRK stock currently worth $379,276.
What does Merck & Co do?
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company’s relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
What does Merck & Co’s logo look like?
Complete history of Mr. Davis stock trades at Baxter International, Duke, Merck & Co, and Duke
Merck & Co executives and stock owners
Merck & Co executives and other stock owners filed with the SEC include:
- Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
- Roger Perlmutter, Executive Vice President, President – Merck Research Laboratories
- Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
- Jennifer Zachary, Executive Vice President, General Counsel
- Peter Wendell, Independent Director
- Wendell Weeks, Independent Director
- Rochelle Lazarus, Independent Director
- Leslie Brun, Lead Independent Director
- Paul Rothman, Independent Director
- Pamela Craig, Independent Director
- Thomas Cech, Independent Director
- Patricia Russo, Independent Director
- Thomas Glocer, Independent Director
- Inge Thulin, Independent Director
- Mary Coe, Independent Director
- Rita Karachun, Senior Vice President Finance – Global Controller
- Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
- Richard DeLuca, Executive Vice President, President – Merck Animal Health
- Frank Clyburn, Executive Vice President, Chief Commercial Officer
- Sanat Chattopadhyay, Executive Vice President and President – Merck Manufacturing Division
- Michael Nally, Executive Vice President, Chief Marketing Officer
- Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
- Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
- Craig B. Thompson, Director
- Adam H Schechter, EVP & Pres-Global Human Health
- Adele D Ambrose, V-P & Chief Com. Officer
- Clark Golestani, EVP & Chief Info Officer
- John H Noseworthy, Director
- Michael J Holston, EVP, Chief Ethics & Compl Ofcr
- Carlos E Represas, Director
- C Robert Kidder, Director
- Weir Mirian M Graddick, Exec. V-P, Human Resources
- Ashley Watson, SVP Chief Ethics & Com Officer
- James H Scholefield, EVP,Chief Info&Digital Officer
- Michael Fleming, SVP Chief Ethics & Com Officer
- William B Jr Harrison, Director
- Michael Rosenblatt, Exec V-P & Chief Med Officer
- John Canan, Senior V-P, Controller
- Stanley F Barshay, Exec V-P Consumer Health Care
- Willie A Deese, Exec. V-P and Pres., MMD
- Anne M Tatlock, Director
- Samuel O Md Thier, Director
- Mervyn Turner, Chief Strategy Officer
- Willam N Kelley, Director
- Richard S Iii Bowles, Exe V-P & Chief Compl Officer
- Peter S Kim, Exec. V-P and Pres., MRL
- Thomas E Shenk, Director
- Bridgette P Heller, Exe.VP & Pres.Con.Hlth.Care
- Raul E Kohan, Exe V-P & Pres, Animal Health
- Steven F Goldstone, Director
- Harry R Jacobson, Director
- Richard T Clark, Chairman, President and CEO
- Peter N Kellogg, Exec. V.P. & C.F.O
- Bruce N Kuhlik, Exec. V.P. and General Counsel
- Cuong V Do, EVP & Chief Strategy Officer
- J Chris Scalet, Exe. VP, Global Services & CIO
